AI Article Synopsis
- Persistence of bactericidal antibodies post-vaccination is crucial for preventing invasive meningococcal disease due to the infection's quick progression.
- The analysis involved data from 7 clinical studies, assessing antibody persistence and booster responses to MenACWY-CRM across adolescents, children, and infants using serum bactericidal assays.
- While high antibody levels were observed initially, there was a notable decline in titers within the first year, particularly in infants and for serogroup A, but a booster dose at 3 to 5 years led to strong immune responses in all age groups.
Article Abstract
Persistence of bactericidal antibodies following vaccination is extremely important for protection against invasive meningococcal disease, given the epidemiology and rapid progression of meningococcal infection. We present an analysis of antibody persistence and booster response to MenACWY-CRM, in adolescents, children and infants, from 7 clinical studies. Immunogenicity was assessed using the serum bactericidal assay with both human and rabbit complement. Post-vaccination hSBA titers were high, with an age- and serogroup-specific decline in titers up to 1 y and stable levels up to 5 y The waning of hSBA titers over time was more pronounced among infants and toddlers and the greatest for serogroup A. However, rSBA titers against serogroup A were consistently higher and showed little decline over time, suggesting that protection against this serogroup may be sustained. A single booster dose of MenACWY-CRM administered at 3 to 5 y induced a robust immune response in all age groups.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4963074 | PMC |
| http://dx.doi.org/10.1080/21645515.2015.1136040 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!